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Purpose of the study
Idiopathic non-cirrhotic portal hypertension (INCPH) has been reported increasingly in patients with chronic HIV infection.
However, several aspects of this disorder remain to be elucidated.The aim of our study was to evaluate the prevalence and risk
factors of HIV associated INCPH.
Methods
All adult HIV patients attending the outpatient clinic between February and September 2011 underwent sonographical spleen
size determination and assessment of portosystemic collaterals. Patients with splenomegaly underwent an extensive ultrasound
examination. Gastroscopy was performed when additional signs of portal hypertension or collaterals were observed. All children
with HIV infection underwent extensive ultrasound examination. INCPH was diagnosed according to the general definition.
Differences between INCPH cases (group 1) and HIV patients treated with didanosine (ddI) without portal hypertension (group 2)
were assessed at HIV diagnosis, start of ddI and INCPH diagnosis.
Summary of results
Four out of 1010 screened adult HIV patients were diagnosed with INCPH (prevalence of 4 ). Hundred of the 1010 screened
patients were treated with ddI. All INCPH patients were treated with ddI, representing an INCPH prevalence of 4% in patients
exposed to ddI. In The Netherlands, 7000 patients were treated with ddI and only 17 are diagnosed with INCPH, suggesting
underdiagnosis in 260 patients. No differences in clinical characteristics predictive for the development of INCPH could be
demonstrated between group 1 and group 2 at HIV infection or start of ddI treatment. INCPH patients were treated longer with
ddI [86 vs. 51 months, pB0.01] and concomitant treatment with ddI and stavudine [21 vs. 4 months, pB0.01]. Corrected for
age and duration of follow-up of HIV, active protein c [0.64 vs. 1.13, pB0.01] and active protein s [0.67 vs. 1.01, pB0.01] levels
were lower in the INCPH group. None of the 38 children with HIV infection were diagnosed with INCPH. None of these children
were ever treated with ddI.
Conclusions
In our study HIV-associated INCPH only occurred in patients exposed to ddI. Awareness for this disorder is warranted considering
the suggested underdiagnosis based on these study results. Risk factors are long term treatment with ddI and concomitant
treatment with stavudine and screening for signs of portal hypertension in this subgroup may be recommended. A possible
pathophysiological role for thrombophilia remains to be elucidated.
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